Trending Stock News

Stuart Arbuckle an Insider in Vertex Pharmaceuticals (VRTX) Sold 138 Shares; NOS SGPS SA ORDINARY SHARES PORTUGAL (ZONNF) SI Increased By 1.48%

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

NOS SGPS SA ORDINARY SHARES PORTUGAL (OTCMKTS:ZONNF) had an increase of 1.48% in short interest. ZONNF’s SI was 3.05 million shares in May as released by FINRA. Its up 1.48% from 3.00M shares previously. The SI to NOS SGPS SA ORDINARY SHARES PORTUGAL’s float is 1.25%. It closed at $5.95 lastly. It is down 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

More important recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: which released: “Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies – RBC” on May 15, 2018, also published article titled: “Vertex Pharmaceuticals Heads Toward An Important Tipping Point”, published: “Vertex Pharmaceuticals Takes a Detour Around the FDA’s Roadblock” on April 30, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was released by: and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery ..” with publication date: May 10, 2018.

The stock increased 0.40% or $0.62 during the last trading session, reaching $156.16. About 971,857 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 76.59% since May 17, 2017 and is uptrending. It has outperformed by 65.04% the S&P500.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on July, 25. They expect $0.42 earnings per share, up 320.00% or $0.32 from last year’s $0.1 per share. VRTX’s profit will be $107.03 million for 92.95 P/E if the $0.42 EPS becomes a reality. After $0.54 actual earnings per share reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -22.22% negative EPS growth.

Since December 11, 2017, it had 0 insider buys, and 45 selling transactions for $106.34 million activity. $960,960 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Sachdev Amit. Silva Paul M sold 3,437 shares worth $544,730. 6,403 shares were sold by ALTSHULER DAVID, worth $965,671. LEIDEN JEFFREY M had sold 99,563 shares worth $15.63M on Tuesday, January 16. $270,358 worth of stock was sold by Chodakewitz Jeffrey on Tuesday, January 16. Bhatia Sangeeta N. sold $1.68M worth of stock or 10,753 shares. $13.47M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by SMITH IAN F.

Investors sentiment decreased to 1.34 in Q4 2017. Its down 0.28, from 1.62 in 2017Q3. It fall, as 53 investors sold Vertex Pharmaceuticals Incorporated shares while 160 reduced holdings. 72 funds opened positions while 213 raised stakes. 232.48 million shares or 0.46% more from 231.42 million shares in 2017Q3 were reported. Hudson Bay Mngmt Ltd Partnership holds 0.16% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 50,000 shares. Moreover, Factory Mutual has 0.28% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Advisory Rech holds 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 1,935 shares. Howe Rusling Inc accumulated 0% or 44 shares. Contravisory Invest Management invested in 30 shares. Natixis holds 487,993 shares or 0.56% of its portfolio. Dekabank Deutsche Girozentrale, a Germany-based fund reported 153,362 shares. Dynamic Cap Mngmt Limited has invested 0.26% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Livforsakringsbolaget Skandia Omsesidigt owns 3,867 shares for 0.06% of their portfolio. Guardian Life Of America owns 0.03% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 816 shares. Smithfield Tru holds 0.02% or 1,132 shares in its portfolio. Moreover, Hbk Lp has 0.19% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Moreover, Whittier Co Of Nevada Inc has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Tocqueville Asset Management Ltd Partnership invested in 0.07% or 42,016 shares. Badgley Phelps & Bell Incorporated reported 3,544 shares or 0.04% of all its holdings.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals has $212.0 highest and $85.0 lowest target. $180.63’s average target is 15.67% above currents $156.16 stock price. Vertex Pharmaceuticals had 102 analyst reports since July 31, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, September 28 by Argus Research. Leerink Swann maintained the shares of VRTX in report on Tuesday, September 26 with “Buy” rating. The rating was upgraded by Vetr to “Hold” on Monday, August 17. The rating was maintained by Jefferies with “Buy” on Wednesday, October 5. The company was maintained on Tuesday, July 18 by Oppenheimer. H.C. Wainwright downgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, October 24 to “Neutral” rating. Piper Jaffray maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, October 26. Piper Jaffray has “Buy” rating and $205.0 target. The firm has “Hold” rating by Cowen & Co given on Wednesday, July 5. JMP Securities maintained it with “Market Outperform” rating and $211 target in Tuesday, February 13 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by BMO Capital Markets on Friday, October 20.

A calculated and well-grounded transaction was made by the EVP\Chief Commercial Officer of Vertex Pharmaceuticals Inc Ma, Mr. Stuart Arbuckle, two days ago, when he sold number of company shares – 138, amounting to $21,498 U.S Dollars, which is calculated based on a stock price of $155.8 per each share. In the last 30 days, he also unloaded 2,125 shares that are worth about $346,396 USD. Right now, Stuart Arbuckle owns 46,892 shares which make up roughly 0.02% of the Company’s total market cap.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *